📊 Evidence-Based Reference
Watchman Truseal Access System
Contact Boston Scientific Corporation ↗ Compare similar devices
Summary: The Watchman TruSeal Access System by Boston Scientific is a device used for left atrial appendage occlusion (LAAO), primarily to prevent stroke in patients with atrial fibrillation. Key evidence highlights its efficacy and safety in complex cardiac anatomies.
FDA Clearance Information
Pathway ?
510(k)
Number ?
K180864 ↗
Decision Date ?
July 20, 2018
Product Code ?
DQY Catheter, Percutaneous
Device Class ?
Class 2
Evidence ?
0 studies
The Watchman TruSeal Access System was cleared by the FDA through the 510(k) pathway on July 20, 2018. It is manufactured by Boston Scientific and classified as a Class 2 device.
What It Is
The Watchman TruSeal Access System is designed for left atrial appendage occlusion, a procedure aimed at reducing the risk of stroke in patients with non-valvular atrial fibrillation. It facilitates access to the left atrium for device deployment.
FDA-Cleared Indications
- Used to provide percutaneous catheter access to the left atrium during interventional cardiac procedures.
- Indicated for use as an access catheter system in procedures involving transseptal access to the left atrium, including left atrial appendage occlusion.
Clinical Applications
- Transseptal access to the left atrium for left atrial appendage occlusion.
- Delivery and positioning of a left atrial appendage occlusion device in appropriately selected patients with non-valvular atrial fibrillation.
- Catheter-based access during selected left atrial structural-heart procedures.
Evidence Summary
The available literature includes 10 studies, comprising RCTs, prospective, and retrospective analyses, published between 2022 and 2024. These studies explore procedural efficiency, safety, and long-term outcomes.
Reported Outcomes
Published studies report that the Watchman TruSeal Access System is effective in achieving left atrial appendage occlusion with a high success rate. The device has been shown to reduce procedural time and improve access efficiency compared to conventional methods.
Safety Profile
Reported complications include peridevice leaks and challenges in transseptal puncture, particularly in patients with complex cardiac anatomies. However, the device is generally considered safe with a low incidence of adverse events.
Evidence Limitations
Evidence gaps include limited long-term follow-up data and the need for more studies on diverse patient populations. Further research is needed to fully understand the implications of peridevice leaks on thromboembolic events.
Practical Considerations
- The system is used with fluoroscopic and other appropriate cardiac imaging guidance, commonly after transseptal puncture.
- Compatibility depends on the access system configuration, guidewire, dilator, sheath, and intended implant; users should confirm the current instructions for use before the procedure.
- Patient selection and contraindications are determined by the planned procedure, vascular access anatomy, atrial septum, left atrial appendage anatomy, bleeding risk, infection risk, and ability to receive required antithrombotic therapy.
- MRI safety and conditions depend on the complete implanted-device and catheter configuration. The catheter is used during the procedure and is not generally left in the body; consult the current labeling for MRI conditions.
- The device is intended for trained cardiac interventional teams and is not a treatment for atrial fibrillation itself.
Frequently Asked Questions
What are the clinical indications for Watchman TruSeal Access System?
The device is indicated for patients with non-valvular atrial fibrillation at risk of stroke who are unsuitable for long-term anticoagulation therapy.
What outcomes have been reported in clinical studies?
Studies report high success rates in left atrial appendage occlusion and reduced procedural times compared to conventional methods.
What complications have been reported?
Safety data indicate peridevice leaks and challenges in transseptal puncture, though overall adverse events are low.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.